"sectionNumber","uuid:ID","name","sectionTitle","instanceType","text","id"
"0","efd82d9d-bad8-4715-b56f-04a682126152","ROOT","Root","NarrativeContent","","NarrativeContent_1"
"0","5711bfd7-c947-47ea-834e-f07d1834648f","SECTION 0","Title Page","NarrativeContent","<div><div class=""container"">
  <div class=""row"">
    <div class=""col-md-8 offset-md-2 text-center"">
      <p><strong><usdm:macro id=""element"" name=""study_identifier""/></strong></p>
    </div>
  </div>
  <div class=""row mt-3"">
    <div class=""col-md-8 offset-md-2 text-center"">
      <p><strong><usdm:macro id=""element"" name=""study_full_title""/></strong></p>
    </div>
  </div>
  <div class=""row mt-3"">
    <div class=""col-md-10 offset-md-1 text-center border"">
      <p><strong>Confidential Information</strong></p>
      <p>
        <small>
          The information contained in this protocol is confidential and is intended for the use of clinical
          investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by
          or distributed to persons not involved in the clinical investigation of glucagon (LY900018), unless such
          persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries.
        </small>
      </p>
      <p>
        <small>
          <b>Note to Regulatory Authorities:</b> This document may contain protected personal data and/or commercially
          confidential information exempt from public disclosure. Eli Lilly and Company requests consultation
          regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of
          Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written
          approval of Eli Lilly and Company or its subsidiaries.
        </small>
      </p>
    </div>
  </div>
  <div class=""row mt-5"">
    <div class=""col-md-8 offset-md-2 text-center"">
      <p>Glucagon (LY900018)</p>
      <p>Eli Lilly Japan K.K Japan</p>
      <p>Clinical Pharmacology Protocol Electronically Signed and Approved by Lilly:</p>
      <p>26 October 2017</p>
      <p>Amendment (<usdm:macro id=""element"" name=""amendment""/>) Electronically Signed and Approved by Lilly on date provided below.</p>
      </p>
    </div>
  </div>
  <div class=""row"">
    <div class=""col-md-3 offset-md-9 text-right"">
      <p>Approval Date: <usdm:macro id=""element"" name=""approval_date""/></p>
    </div>
  </div>
</div></div>","NarrativeContent_2"
"1","729dee1d-c3e5-444b-86f8-40df0f3c6834","SECTION 1","Protocol Synopsis","NarrativeContent","<div>
  <p><b>Title of Study:</b></p>
  <p>A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced
    Hypoglycemia in Japanese Patients with Diabetes Mellitus</p>
  <p><b>Rationale:</b></p>
  <usdm:macro id=""element"" name=""study_rationale"" />
  <p><b>Objectives Endpoints:</b></p>
  <table class=""table"">
    <tr>
      <th>Objectives</th>
      <th>Endpoints</th>
    </tr>
    <tr>
      <td>
        <p><b>Primary</b></p>
        <p>
          <usdm:macro id=""xref"" name=""OBJ1"" klass=""Objective"" attribute=""text""></usdm:macro>
        </p>
      </td>
      <td>
        <p>&nbsp;</p>
        <p>
          <usdm:macro id=""xref"" name=""END1"" klass=""Endpoint"" attribute=""text""></usdm:macro>
        </p>
      </td>
    </tr>
    <tr>
      <td>
        <p><b>Secondary</b></p>
        <ul>
          <li>
            <p>
              <usdm:macro id=""xref"" name=""OBJ2"" klass=""Objective"" attribute=""text""></usdm:macro>
            </p>
          </li>
          <li>
            <p>
              <usdm:macro id=""xref"" name=""OBJ3"" klass=""Objective"" attribute=""text""></usdm:macro>
            </p>
          </li>
          <li>
            <p>
              <usdm:macro id=""xref"" name=""OBJ4"" klass=""Objective"" attribute=""text""></usdm:macro>
            </p>
          </li>
        </ul>
      </td>
      <td>
        <p>&nbsp;</p>
        <ul>
          <li>
            <p>
              <usdm:macro id=""xref"" name=""END2"" klass=""Endpoint"" attribute=""text""></usdm:macro>
            </p>
          </li>
          <li>
            <p>
              <usdm:macro id=""xref"" name=""END3"" klass=""Endpoint"" attribute=""text""></usdm:macro>
            </p>
          </li>
          <li>
            <p>
              <usdm:macro id=""xref"" name=""END4"" klass=""Endpoint"" attribute=""text""></usdm:macro>
            </p>
          </li>
        </ul>
      </td>
    </tr>
  </table>

  <p><small>Abbreviations: AE = adverse event; AUC = area under the concentration versus time curve; BG max = maximal
      plasma glucose concentration; C max = maximal concentration; IMG = intramuscular glucagon; PD = pharmacodynamics;
      PG = plasma glucose; PK = pharmacokinetics; SAE = serious adverse event; TEAE = treatment-emergent adverse event;
      T max = time to maximal concentration.</small></p>

  <p><b>Summary of Study Design:</b></p>
  <p>Study I8R-JE-IGBJ is a Phase 3, multicenter, randomized, open-label, active comparator, single-dose, 2-treatment,
    2-period crossover study in Japanese patients with T1DM and patients with T2DM.</p>

  <p><b>Treatment Arms and Planned Duration for an Individual Patient:</b></p>
  <p>LY900018: Single 3-mg dose; nasal administration by study site personnel<br />
    IMG (GlucaGen, Novo Nordisk A/S): Single 1-mg dose; IM injection by study site personnel</p>
  <p>Patients will undergo a screening examination within 28 days prior to enrollment. Patients will be administered a
    single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14 days. Patients will return
    for a follow-up visit 26 to 30 days after the last study treatment.</p>

  <p><b>Number of Patients:</b></p>
  <p>Seventy five (<usdm:macro id=""xref"" klass=""StudyDesignPopulation"" name=""STUDY_POP""
      attribute=""@plannedEnrollmentNumber/Range/maxValue""></usdm:macro>) patients may be enrolled in order to have at
    least <usdm:macro id=""xref"" klass=""StudyDesignPopulation"" name=""STUDY_POP""
      attribute=""@plannedCompletionNumber/Range/maxValue""></usdm:macro> patients (at least <usdm:macro id=""xref"" klass=""StudyCohort""
      name=""T1DM"" attribute=""@plannedCompletionNumber/Range/maxValue""></usdm:macro> patients with T1DM and <usdm:macro
      id=""xref"" klass=""StudyCohort"" name=""T2DM"" attribute=""@plannedCompletionNumber/Range/maxValue""></usdm:macro>
    T2DM, respectively) complete both periods with evaluable primary outcome. If patients discontinue from the study
    before completion of both periods with evaluable primary outcome for any reason, the patient may be replaced.
    Replacement
    should not occur beyond <usdm:macro id=""xref"" klass=""StudyDesignPopulation"" name=""STUDY_POP""
      attribute=""@plannedEnrollmentNumber/Range/maxValue""></usdm:macro> patients enrolled, if it is expected to have at
    least <usdm:macro id=""xref"" klass=""StudyDesignPopulation"" name=""STUDY_POP""
      attribute=""@plannedCompletionNumber/Range/maxValue""></usdm:macro> patients complete the study.</p>

  <p><b>Statistical Analysis:</b></p>
  <p>A total of 66 completers are required in the study in order to achieve the primary objective with at least 90%
    power using the following assumptions:</p>
  <ul>
    <li>
      <p>A treatment success rate of 98% for both treatments</p>
    </li>
    <li>
      <p>A non-inferiority margin (NIM) of 10%</p>
    </li>
    <li>
      <p>One-sided alpha level of 0.025</p>
    </li>
    <li>
      <p>A within-patient correlation of zero between 2 treatment visits</p>
    </li>
  </ul>
  <p>The primary analysis will be a treatment comparison
    of the percentage of patients, including both T1DM and T2DM, who achieve treatment success. The percentage of
    patients who achieve treatment success within each treatment group and the difference in the percentages between the
    2
    treatment groups will be computed. A 2-sided 95% confidence interval (CI) will be obtained from the 1-sample mean of
    the paired differences in primary outcome (1=outcome observed; 0=outcome not observed) across 2 treatment visits.
    Non-inferiority of LY900018 will be declared if the upper limit of the 2-sided 95% CI constructed on the difference
    in percentage (IMG - LY900018) is less than the NIM of 10%.</p>
</div>""","NarrativeContent_3"
"2","2228b0f6-ccdf-4e77-91db-79dc4e988b17","SECTION 2","Schedule of Activities","NarrativeContent","<div><usdm:macro id=""note"" text=""The following SoA timelines are auto generated using the detailed study design held within the USDM.""/> <usdm:macro id=""section"" name=""soa""/></div>","NarrativeContent_4"
"3","9024e952-00e8-44d9-afaa-e1b0d73e100d","SECTION 3","Introduction","NarrativeContent","<div></div>","NarrativeContent_5"
"3.1.","824cbcc5-d4eb-4bf0-99e2-eb10a398e5e5","SECTION 3.1.","Study Rationale","NarrativeContent","<div><usdm:macro id=""element"" name=""study_rationale""/></div>","NarrativeContent_6"
